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Holding Back the Tide of Antibiotic ResistanceUntil the wide production of penicil-
lin in the 1940s, bacterial infections
were a prominent cause of deaths
and disabilities around the world.
Hospitals focused mainly on treat-
ing infectious diseases such as
pneumonia, syphilis, tuberculosis,
and other common infections. Peni-
cillin, effective against a broad spec-
trum of pathogenic bacteria and
with low toxicity to humans, literally
revolutionized the way infectious
diseases were treated and set the
model for all of modern chemother-
apy. As use of penicillin and penicil-
lin-based antibiotics spread, deaths
from bacterial diseases were re-
duced to such an extent that most
infections are now considered in-
convenient, rather than life threaten-
ing.
But as antibiotic use became rou-
tine, an alarming trend emerged.
Bacteria rapidly developed resis-
tance to penicillin, and cases that
used to require a single shot of pen-
icillin to cure were requiring longer
treatment periods and newer drugs.
In recent years, several strains of
bacteria emerged that are resistant
to most common antibiotics. Many
physicians and scientists foresee
a major crisis.
The Centers for Disease Control
and Prevention estimates that every
year, 2 million Americans acquire in-
fections while in hospitals and
90,000 die and that about 70% of
the hospital infections are resistant
to at least one class of antibiotics
[1]. Most of the multidrug-resistant
infections have been postsurgical
and posed a threat to the immuno-
compromised and the seriously ill.
However, now we are seeing an in-
crease in drug-resistant community-
acquired infections, picked up not
just in hospitals and nursing homes
but in the places where we live and
work.
Dr. Stuart Levy, professor of Mo-
lecular Biology, Microbiology, and
Medicine at Tufts University and co-
founder of Paratek Pharmaceuti-
cals, a Boston biotech companythat develops antibiotics to combat
drug-resistant bacteria, claims that
antibiotic resistance is not just a
problem for the immunocompro-
mised. He cites the examples of
Streptococcus pneumoniae, which
can cause ear infections in normally
healthy children, and Staphylococ-
cus aureus, a common skin patho-
gen. Both can lead to flesh-eating
bacterial infections and are multi-
drug resistant. They have the poten-
tial of infecting healthy people—and
they are spreading.
‘‘With antibiotics, it is like
we are always chasing
our tail. We find one, we
overuse it, we create re-
sistance. We are back at
square one,’’ Dr. Stuart
Levy said.
No New Drugs
Since the advent of penicillin, a
dozen chemically different antibac-
terial structural scaffolds have
been discovered. These scaffolds
function as building blocks for nu-
merous optimized antibiotics and
antibacterial drugs. Despite the
emerging need and intensive re-
search, only two truly novel chemo-
type scaffolds, the oxazolidinone
core linezolid (Zyvox) and the lipo-
peptides (Cubicin), have emerged
in the last thirty years; and Zyvox,
Cubicin, and Ketek (an antibacterial
drug of the ketolide family) are the
only novel medicines that have been
approved by the FDA and reached
the market in that time [2]. There
have been many different types of
antibiotics or antimicrobials, which
are synthetic antibiotics, approved
for the market. Most have been var-
iants of existing drugs or cocktails of
drugs with complementary or syner-
gistic effects that were optimized to
work better for certain infections. Inthese cases, the mechanism of ac-
tion or group of bacteria targeted is
not novel.
According to Levy, the discovery
and synthesis of antibiotic/antibac-
terial drugs and the process of
bringing them to market is extremely
costly. Over the years, the major
breakthroughs and discoveries were
made by large pharmaceutical com-
panies. Now half of the large phar-
maceutical companies have left the
antibiotics field for more lucrative
pastures. As a result, conventional
avenues for research and develop-
ment of new antibiotics and antibac-
terial drugs have atrophied.
‘‘The low-lying fruit have been dis-
covered. It has been 20 years we’ve
been looking at genes and ge-
nomes, but we haven’t really come
up with a new antibiotic by that ap-
proach,’’ Levy says. Biotech compa-
nies like Paratek are filling the void.
Some big pharmaceutical compa-
nies have stayed in the game by ei-
ther sponsoring or working with bio-
tech companies.
Chasing Our Tail
Antibiotics work against bacteria via
various mechanisms: interfering
with protein synthesis (eg., tetracy-
cline), DNA synthesis (eg., ofloxa-
cin), blocking cell wall synthesis
(eg., amoxicillin), cell membrane
permeability (eg., colistin), inhibiting
an enzyme (eg., cotrimoxazole), or
membrane disruption (eg., dapto-
mycin). Correspondingly, antibiotic
resistance can evolve by several
paths. Bacteria can develop the
ability to dispose of antibiotics effi-
ciently. Genetic diversity in the bac-
teria population can cause natural
variation at the antibiotics’ point of
action; as a result, the effectiveness
of the antibiotics on the individual
bacterium varies, and natural selec-
tion for the more resistant bacteria
occurs. Sometimes mutation ren-
ders the antibiotics’ point of action
completely ineffective. The antibi-
otics that inhibit protein synthesis
on the ribosome are some of the
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up resistance to because the chan-
ces that this very central mechanism
would be totally modified by muta-
tion are low.
Clinicians and researchers are
working together to develop the
next generation of antibiotics. To
prevent resistance from occurring,
clinicians strive to administer antibi-
otics as specifically targeted to the
pathogen as possible (the worst
strategy is to administer broad
spectrum antibiotics) and give
enough of a dose long enough to as-
sure complete healing. But how do
researchers develop resistance-
proof antibiotics? ‘‘I think we are
hearing and reading more about
searching for alternatives to antibi-
otics,’’ Levy says. ‘‘With antibiotics,
it is like we are always chasing our
tail. We find one, we overuse it, we
create resistance. We are back at
square one. By targeting nonessen-
tial features of the cell, but those in-
volved in the infection process itself,
we avoid selecting resistance but
prevent or limit infection.’’ New ap-
proaches are clearly essential for
preserving the standards of health
care down the road.
Battle Strategies
Companies are pursuing various
strategies. Among them, Paratek
Pharmaceuticals, Biosignal, 4SC,
and BalaPharm International are in-
vestigating regulation of transcrip-
tion factors and interfering with bac-
terial quorum sensing; Genzyme
and Cengent Therapeutics are
working with toxin inhibitors; and
Essential Therapeutics and Daiichi
are using efflux pump inhibitors. Os-
cient’s Ramoplanin disrupts cell
walls and is currently targeting the
sort of Clostridium difficile infec-
tions that have been killing people
in hospitals [3]. Using crystallo-
graphic data, Rib-X Pharmaceuti-
cals designs antibiotics that specif-
ically target ribosomes. Ribonovix
produces bioengineered plasmids
that encode mutant rRNA (the build-
ing block of ribosomes) to aid the
design of drugs that can combat
specific resistance-causing muta-
tions.
Paratek (http://www.paratek.
com/) is targeting the virulence of
pathogens, which is their ability to
infect an organ in the body and gen-
erate disease. The technologicalplatform of the company is based
on research from Dr. Stuart Levy’s
laboratory at Tufts University. Levy’s
group discovered a class of molecu-
lar switches or transcription factors,
the Mar proteins, used by bacteria to
resist antibiotics and cause infec-
tion. For instance, these events in
E. coli are regulated by proteins
called MarA, SoxS, and Rob.
Paratek has shown that the func-
tions of the Mar proteins are regu-
lated by a group of small molecules.
These small molecules can be used
as drugs to inhibit the ability of the
proteins to function as transcription
factors. When the Mar protein is in-
hibited, bacteria loses their viru-
lence. Paratek has identified several
small molecules that work directly
on Mar proteins from E. coli, Yersinia
pseudotuberculosis (a relative of the
organism that causes plague), and
Pseudomonas aeruginosa in in vitro
assays. They have also achieved
proof-of-concept studies by inhibit-
ing the ability of E. coli [2] and re-
cently Y. pseudotuberculosis to in-
fect the kidneys and lungs of mice,
respectively. The drawback of this
approach is that in some cases, in-
fection can take place via a different
biochemical route, even if a specific
Mar protein is inhibited. In addition,
Paratek is developing modified tet-
racyclines.
Bug Sex Can Kill
Another novel approach is being
pursued by Wisconsin-based Con-
juGon (http://www.conjugon.com/).
This eight-person startup is using
bacterial sexual reproduction to
spread lethal genes in pathogen
communities. When the lethal genes
are expressed, the bacterial popula-
tion dies out.
‘‘I’m a plasmid biologist,’’ says
Marcin Filutowicz, professor of bac-
teriology at the University of Wiscon-
sin-Madison, and one of ConjuGon’s
founders. ‘‘Bacterial plasmids are
extra chromosomal elements that
bacteria don’t need to live. They
transfer DNA molecules among bac-
teria. They carry genes which fre-
quently encode for antibiotic resis-
tance. Most of the DNA that is
transferred between bacteria is
done through plasmid exchange.’’
ConjuGon engineers specific plas-
mids with DNA that encodes toxins
as well as benign bacteria that are
immune to the toxins encoded bythe plasmids. When immune bacte-
ria transfer the plasmid that encodes
for the toxins to the recipient bacte-
ria, such as a pathogen like Pseudo-
monas aeruginosa, during conjuga-
tion the toxin is expressed, killing
the pathogen.
‘‘It is a Trojan-horse-like approach
where we introduce a DNA molecule
from donor to recipient and then ex-
press in the recipients multiple
toxins or single toxins,’’ says Filuto-
wicz. ‘‘When we express multiple
toxins, we reduce the probability
for the recipient bacteria to acquire
immunity.’’
ConjuGon is targeting genes that
encode for antibiotics that block
a certain RNA polymerase at several
different locations in bacteria. The
company has a patent on ‘‘Sigma
Binding of RNA Polymerase and
Uses Therof’’ for its method of high-
throughput screening for small-mol-
ecule drugs that interfere with the
binding of transcription factor sigma
to the core RNA polymerase. Conju-
Gon chose this target because it is
unlikely that bacteria would mutate
in enough multiple ways to evade
a compound that interferes with
this interaction.
Conjugon recently received a
phase I SBIR grant from the Army
to do research on a treatment for an-
tibiotic-resistant Acineobacter bau-
mannii infections contracted by
wounded soldiers in Iraq and Afgha-
nistan. Additionally, Ravi Shankar,
associate professor, Department of
Surgery and Cell Biology, Neurobiol-
ogy & Anatomy Burn and Shock
Trauma Unit at Loyola University
Medical Center, is conducting the
proof-of-concept studies on Conju-
Gon’s approach on mice. Shankar
is interested in ConjuGon’s ap-
proach as a specialized or adjunct
therapy for patients with burn or
trauma wounds who have a long
healing process. ‘‘Much of the time,
especially with burn-wound cases,
it is not about life or death. It is about
achieving adequate wound cover-
age with grafts or synthetic material
so the person can heal faster,’’ Shan-
kar says. ‘‘But unfortunately, if you
have an infection, many of the grafts
fail. They lift off.’’ Conventional anti-
biotic therapy can be problematic
as the antibiotic has to be delivered
to the actual wound area of the pa-
tient. Thus, a systemic antibiotic is
not enough. A majority of time,
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antibiotics and antimicrobials, such
as topical silver emulsions.
Shankar says that in the mouse
studies that pathogens were totally
eliminated within 30 min of adminis-
tering ConjuGon treatment. ‘‘It actu-
ally works.. We have to see if it
works on human beings,’’ Shankar
says.
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